Fulgent Genetic (NASDAQ:FLGT) insider Ming Hsieh bought 10,504 shares of the business’s stock in a transaction that occurred on Tuesday, November 14th. The shares were purchased at an average price of $3.30 per share, for a total transaction of $34,663.20. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Ming Hsieh also recently made the following trade(s):

  • On Thursday, November 16th, Ming Hsieh bought 2,205 shares of Fulgent Genetic stock. The shares were purchased at an average price of $3.23 per share, for a total transaction of $7,122.15.
  • On Thursday, November 9th, Ming Hsieh bought 11,520 shares of Fulgent Genetic stock. The shares were purchased at an average price of $3.47 per share, for a total transaction of $39,974.40.

Shares of Fulgent Genetic (NASDAQ FLGT) traded up $0.07 during trading on Friday, reaching $3.26. 109,890 shares of the company’s stock traded hands, compared to its average volume of 63,834. The stock has a market capitalization of $58.10 and a price-to-earnings ratio of 166.00. Fulgent Genetic has a one year low of $2.72 and a one year high of $13.90.

WARNING: “Ming Hsieh Purchases 10,504 Shares of Fulgent Genetic (FLGT) Stock” was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://theolympiareport.com/2017/11/18/ming-hsieh-purchases-10504-shares-of-fulgent-genetic-flgt-stock.html.

FLGT has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Fulgent Genetic from a “sell” rating to a “hold” rating in a research note on Monday, September 18th. Piper Jaffray Companies restated an “overweight” rating and set a $7.00 target price (down from $10.00) on shares of Fulgent Genetic in a research note on Wednesday, August 9th. Credit Suisse Group cut their target price on shares of Fulgent Genetic from $10.00 to $7.50 and set an “outperform” rating on the stock in a research note on Tuesday, November 7th. ValuEngine upgraded shares of Fulgent Genetic from a “sell” rating to a “hold” rating in a research note on Monday, October 2nd. Finally, Raymond James Financial, Inc. lowered shares of Fulgent Genetic from an “outperform” rating to a “mkt perform” rating in a research note on Tuesday, November 7th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $7.25.

A number of institutional investors have recently made changes to their positions in the business. William Blair Investment Management LLC increased its stake in Fulgent Genetic by 10.4% in the second quarter. William Blair Investment Management LLC now owns 640,219 shares of the company’s stock valued at $4,091,000 after purchasing an additional 60,508 shares during the last quarter. Granahan Investment Management Inc. MA increased its stake in Fulgent Genetic by 145.5% in the third quarter. Granahan Investment Management Inc. MA now owns 238,232 shares of the company’s stock valued at $1,141,000 after purchasing an additional 141,182 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in Fulgent Genetic in the first quarter valued at approximately $122,000. Finally, Wells Fargo & Company MN increased its stake in Fulgent Genetic by 2,046.0% in the first quarter. Wells Fargo & Company MN now owns 10,730 shares of the company’s stock valued at $118,000 after purchasing an additional 10,230 shares during the last quarter. Institutional investors own 16.78% of the company’s stock.

About Fulgent Genetic

Fulgent Genetics, Inc is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes.

Receive News & Ratings for Fulgent Genetic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetic and related companies with Analyst Ratings Network's FREE daily email newsletter.